A Comparative Analysis of Prognostic Factors for Functional Outcomes in Patients With Acute Subdural Hematoma

June 18, 2024 updated by: Michal Soták, Charles University, Czech Republic
Acute subdural hematoma (ASDH) is the most common intracranial traumatic lesion that requires surgical intervention. Although there is extensive published research on acute subdural, there remains uncertainty regarding mortality risk and functional outcomes for patients. This study aims to evaluate the effectiveness of contemporary scoring systems in different age groups of ASDH patients to predict functional outcomes.

Study Overview

Detailed Description

Acute subdural hematoma (ASDH) is the most common intracranial traumatic lesion that requires surgical intervention. Although there is extensive published research on acute subdural, there remains uncertainty regarding mortality risk and functional outcomes for patients. This study aims to evaluate the effectiveness of contemporary scoring systems in different age groups of ASDH patients to predict functional outcomes. It is our belief that this research will provide valuable insights on the risk of mortality and functional outcomes for ASDH patients. Several clinical and radiologic factors have been identified within the general population that correlate with mortality rates and functional outcomes. There are a number of factors that must be considered in the evaluation of a patient with traumatic brain injury, and a comprehensive assessment is necessary to determine the best course of treatment.

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Praha, Czechia, 16209
        • Recruiting
        • Military University Hospital Prague
        • Contact:
        • Principal Investigator:
          • Tomáš Tyll, M.D., Ph.D.
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients who underwent surgery due to acute subdural hematoma in a single institution.

Description

Inclusion Criteria:

  • surgery due to ASDH
  • 12 months of follow-up
  • functional outcome measured by the Glasgow Outcome Scale Extended (GOSE).

Exclusion Criteria:

  • none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Surgery Group
Adult patients who underwent surgery due to acute subdural hematoma
Adult patients who underwent decompressive craniectomy with evacuation of subdural hematoma.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Level of consciousness at time of injury
Time Frame: through study completion, an average of 1 year
The level of consciousness (using the Glasgow Coma Scale, 3-15 points, higher score means a better outcome) at the time of injury is analyzed.
through study completion, an average of 1 year
Initial size of subdural hematoma
Time Frame: through study completion, an average of 1 year
Initial size of subdural hematoma measured in millimetres using CT scan.
through study completion, an average of 1 year
Initial midline shift
Time Frame: through study completion, an average of 1 year
Initial size of midline shift measured in millimetres using CT scan.
through study completion, an average of 1 year
Chronic use of anti-clotting medication
Time Frame: once at time of admission
The number of patients on chronic anticoagulation therapy will be the subject of analysis.
once at time of admission
Trauma severity analyzed using Injury Severity Score (ISS).
Time Frame: once at time of admission
Trauma severity analyzed using Injury Severity Score. The ISS scores ranges from 1 to 75 points (Higher scores correspond to more severe injury and a higher risk of death).
once at time of admission
Severity of illness analyzed using Acute Physiology and Chronic Health Evaluation II score (APACHE II)
Time Frame: within 24 hours of admission
Severity of patient illness will be analyzed using Acute Physiology and Chronic Health Evaluation II score (APACHE II) which ranges from 0 to 71 points. Higher scores correspond to more severe disease and a higher risk of death.
within 24 hours of admission
The Glasgow Outcome Scale (GOS) at the time of discharge from the Intensive Care (IC).
Time Frame: through study completion, an average of 1 year
The Glasgow Outcome Score allowing the objective assessment of the patient´s recovery after trauma brain injury. Allows a prediction of the long-term course of rehabilitation to return to work and everyday life. It uses five categories: 1. Death, 2. Persistent vegetative state, 3. Severe disability, 4. Moderate disability, 5. Low disability.
through study completion, an average of 1 year
The Glasgow Outcome Scale Extended (GOSE) evaluation of global disability and recovery after 6 months.
Time Frame: 6 months follow up

The Glasgow Outcome Scale Extended (GOSE) is an expanded version of the Glasgow Outcome Scale for evaluation of global disability and recovery after traumatic brain injury. It uses eight categories: 1. Death, 2. Vegetative state, 3. Lower severe disability, 4. Upper severe disability, 5. Lower moderate disability, 6. Upper moderate disability - some disability but can potentially return to some form of employment, 7. Lower good recovery - minor physical or mental defect, 8. Upper good recovery - full recovery.

A GOSE analysis will be performed on a patient who has undergone evacuation of a subdural hematoma 6 months after the trauma.

6 months follow up
The Glasgow Outcome Scale Extended (GOSE) evaluation of global disability and recovery after 12 months.
Time Frame: 12 months follow up

The Glasgow Outcome Scale Extended (GOSE) is an expanded version of the Glasgow Outcome Scale for evaluation of global disability and recovery after traumatic brain injury. It uses eight categories: 1. Death, 2. Vegetative state, 3. Lower severe disability, 4. Upper severe disability, 5. Lower moderate disability, 6. Upper moderate disability - some disability but can potentially return to some form of employment, 7. Lower good recovery - minor physical or mental defect, 8. Upper good recovery - full recovery.

A GOSE analysis will be performed on a patient who has undergone evacuation of a subdural hematoma 12 months after the trauma.

12 months follow up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of revisions.
Time Frame: 24 hours
The number of re-operations that are required within 24 hours of the initial procedure will be analyzed.
24 hours
Time from injury to surgery.
Time Frame: 24 hours
The time from the onset of the injury to the evacuation of the subdural hematoma will be analyzed.
24 hours
Time of operation.
Time Frame: up to 4 hours
The operative time of the evacuation of the subdural hematoma will be analyzed.
up to 4 hours
The need for reversal of the effects of anticoagulants.
Time Frame: 24 hours
The number of cases of need for reversal of the effect of chronic anticoagulant medication will be analyzed.
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Tomáš Tyll, M.D., Ph.D., Charles University, Czech Republic

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2024

Primary Completion (Estimated)

September 1, 2024

Study Completion (Estimated)

November 1, 2024

Study Registration Dates

First Submitted

March 24, 2024

First Submitted That Met QC Criteria

April 8, 2024

First Posted (Actual)

April 15, 2024

Study Record Updates

Last Update Posted (Actual)

June 21, 2024

Last Update Submitted That Met QC Criteria

June 18, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acquired Brain Injury

Clinical Trials on Decompressive craniectomy with evacuation of subdural hematoma

3
Subscribe